Acadia Pharmaceuticals | ACAD - Cash And Equivalent

Stock Price
21.40
Daily Change
-0.69 -3.12%
Monthly
0.71%
Yearly
-3.86%
Q2 Forecast
20.97

Acadia Pharmaceuticals reported $851.46M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
ALKERMES USD 351.55M 37.02M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Cara Therapeutics USD 20.73M 684K Dec/2025
Corcept Therapeutics USD 108.74M 11.76M Mar/2026
Cytokinetics USD 129.84M 7.32M Mar/2026
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Moderna USD 1.91B 687M Mar/2026
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Prothena USD 329.46M 21.93M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026